ARQT - Arcutis Biotherapeutics  - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

ARQT is currently covered by 10 analysts with an average price target of $28.81. This is a potential upside of $15.54 (117.11%) from yesterday's end of day stock price of $13.27.

Arcutis Biotherapeutics 's activity chart (see below) currently has 59 price targets and 81 ratings on display. The stock rating distribution of ARQT is 85% BUY and 15% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 24.32% with an average time for these price targets to be met of 64.6 days.

Highest price target for ARQT is $21, Lowest price target is $15, average price target is $15.57.

Most recent stock forecast was given by SERGE BELANGER from NEEDHAM on 23-May-2025. First documented stock forecast 25-Feb-2020.

Currently out of the existing stock ratings of ARQT, 34 are a BUY (85%), 6 are a HOLD (15%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$20

$6.96 (53.37%)

$20

11 days ago
(23-May-2025)

3/20 (15%)

$6.02 (43.06%)

275

Buy

$19

$5.96 (45.71%)

$19

2 months ago
(03-Apr-2025)

0/4 (0%)

$2.84 (17.57%)

Buy

2 months ago
(03-Apr-2025)

1/1 (100%)

$9.67 (36.73%)

27

Hold

$15

$1.96 (15.03%)

$11

3 months 7 days ago
(27-Feb-2025)

3/5 (60%)

$2.2 (17.19%)

41

Buy

$21

$7.96 (61.04%)

$20

3 months 8 days ago
(26-Feb-2025)

3/17 (17.65%)

$8.8 (72.13%)

273

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is ARQT (Arcutis Biotherapeutics ) average time for price targets to be met?

On average it took 64.6 days on average for the stock forecasts to be realized with a an average price target met ratio 24.32

Which analyst has the current highest performing score on ARQT (Arcutis Biotherapeutics ) with a proven track record?

GRAIG SUVANNAVEJH

Which analyst has the most public recommendations on ARQT (Arcutis Biotherapeutics )?

Graig Suvannavejh works at MIZUHO and has 3 price targets and 2 ratings on ARQT

Which analyst is the currently most bullish on ARQT (Arcutis Biotherapeutics )?

Louise Chen with highest potential upside - $36.96

Which analyst is the currently most reserved on ARQT (Arcutis Biotherapeutics )?

Chris Shibutani with lowest potential downside - -$7.04

Arcutis Biotherapeutics  in the News

Arcutis Biotherapeutics: Zoryve foam treatment resulted in major improvements

Arcutis Biotherapeutics (ARQT) announced that the Journal of American Medical Association Dermatology published the results from a pivotal Phase 3 study evaluating the efficacy and safety of ZORYVE foam 0.3% as a once-daily monotherapy treatment for psoriasis of the scalp and body. The study showed that treatment with investigational ZORYVE foam resulted in significant improvements...

Arcutis Biotherapeutics First Quarter 2025 Earnings: Beats Expectations

Arcutis Biotherapeutics (NASDAQ:ARQT) First Quarter 2025 Results Key Financial Results Revenue: US$65.8m (up 33% from 1Q 2024). Net loss: US$25.1m (loss narrowed by 29% from 1Q 2024). US$0.20 loss per share (improved from US$0.32 loss in 1Q 2024). We’ve discovered 1 warning sign about Arcutis Biotherapeutics. View them for free.NasdaqGS:ARQT Earnings and Revenue Growth May...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?